143 related articles for article (PubMed ID: 18489517)
1. The cost-effectiveness of atypicals in the UK.
Heeg B; Buskens E; Botteman M; Caleo S; Ingham M; Damen J; de Charro F; van Hout B
Value Health; 2008 Dec; 11(7):1007-21. PubMed ID: 18489517
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.
Davies LM; Lewis S; Jones PB; Barnes TR; Gaughran F; Hayhurst K; Markwick A; Lloyd H;
Br J Psychiatry; 2007 Jul; 191():14-22. PubMed ID: 17602120
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
8. A pharmacoeconomic analysis of compliance gains on antipsychotic medications.
Damen J; Thuresson PO; Heeg B; Lothgren M
Appl Health Econ Health Policy; 2008; 6(4):189-97. PubMed ID: 19382819
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine.
Davies LM; Barnes TR; Jones PB; Lewis S; Gaughran F; Hayhurst K; Markwick A; Lloyd H;
Value Health; 2008; 11(4):549-62. PubMed ID: 18179662
[TBL] [Abstract][Full Text] [Related]
11. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.
Graham CN; Mauskopf JA; Lawson AH; Ascher-Svanum H; Bruhn D
Value Health; 2012 Jan; 15(1):55-64. PubMed ID: 22264972
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
Haycox A
Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of atypical antipsychotic medications versus conventional medication.
Hanrahan P; Luchins DJ; Fabian R; Tolley G
Expert Opin Pharmacother; 2006 Sep; 7(13):1749-58. PubMed ID: 16925502
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study.
Salkever D; Slade E; Karakus M
Pharmacoeconomics; 2006; 24(2):123-39. PubMed ID: 16460134
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany.
Stargardt T; Edel MA; Ebert A; Busse R; Juckel G; Gericke CA
J Clin Psychopharmacol; 2012 Oct; 32(5):602-7. PubMed ID: 22926592
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].
Quitian Reyes H; Arciniegas Barrera JA; Bohórquez Peñaranda A; Gómez Restrepo C
Rev Colomb Psiquiatr; 2016; 45(2):67-74. PubMed ID: 27132755
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]